Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism SFRP2 antagonists(secreted frizzled related protein 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | 24 Aug 2022 | |
Osteosarcoma | Preclinical | US | - |